Compare Boston Scientific Corporation (BSX) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Marqeta Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while Marqeta Inc trades at $16.21 (market cap $1.70B). The key difference: Boston Scientific Corporation is far larger — about 39× Marqeta Inc's market cap. Which is the better fit depends on your goals.
| BSX | MQ | |
|---|---|---|
Market Cap | $66.37B | $1.70B |
Sector | Health | Technology |
52-Week High | $108.14 | $27.32 |
52-Week Low | $42.63 | $15.04 |
Enterprise Value | $75.94B | $999.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Marqeta (MQ) trades at $16.43, up 3.53% with a bullish technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with revenue growth from $507M in 2024 to $625M in 2025. A recent 1-for-4 reverse stock split took effect on July 1, 2026. Cash flow improved to a net positive $86M in 2025. Analyst consensus is a $19 price target with 32% buy ratings.
Outlook is cautiously optimistic given earnings volatility and high valuation multiples. Opportunities include European expansion and credit product growth, but risks involve thin net margins and potential fiduciary duty lawsuits. The stock's upside depends on sustained profitability and execution of strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
